

del
C2
118. (New) The method of Claim 117, wherein the FATP comprises the amino acid sequence of SEQ ID NO: 25.

119. (New) The method of Claim 117, wherein the FATP comprises the amino acid sequence of SEQ ID NO: 27.

a²
word
120. (New) The method of Claim 117, wherein the FATP comprises the amino acid sequence of SEQ ID NO: 49.

121. (New) The method of Claim 117, wherein the FATP comprises the amino acid sequence of SEQ ID NO: 102.

122. (New) The method of Claim 117, wherein the FATP comprises the amino acid sequence of SEQ ID NO: 55.

123. (New) The method of Claim 117, wherein the FATP comprises the amino acid sequence of SEQ ID NO: 57.

Add C3

REMARKS

This application was originally filed with Claims 1-81. In the present Office Action, mailed from the United States Patent and Trademark Office on March 26, 2001, the claims were placed into Groups I-VII, and Applicants were requested to elect one group for prosecution. Should Applicants' election be directed to Groups I, II, IV, V, VI or VII, Applicants were further required to elect a single species.

In this Response and Preliminary Amendment, Applicants have elected Group III for prosecution. Therefore, it is Applicants' understanding that no election of species is required.

In this Amendment, Applicants have also cancelled Claims 1-72, 75-77 and 79, amended Claim 73 and added Claims 82-123. As Applicants' Attorney informed Examiner Wegert, a co-pending application, United States Serial No. 09/232,201, is presently being prosecuted. The claims originally filed in that application, although many have now been amended, were identical

to those originally filed in this application. Therefore, the present claim cancellations, amendments and additions are primarily being made for the purpose of ensuring that the claims of the two applications are not directed to redundant subject matter. The amendment to Claim 73 is also made for the purpose of ensuring that the acronym FATP is presented properly in the first claim.

The amendment to Claim 73, as well as the newly added claims, find support throughout the specification, examples, figures and claims of the application as originally filed. In particular the claims find support in the originally filed claims of Group III and the specification at pages 21-22, lines 27-29 and lines 1-13, respectively. No new matter has been added by the amendment or the addition of these claims. Moreover, the amended and newly added claims, patterned on the original claims of elected Group III, are properly examined in this application.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (781) 861-6240.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Linda M. Chinn

Registration No. 31,240

Telephone (781) 861-6240

Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *June 26, 2001*

MARKED UP VERSION OF AMENDMENTSClaim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)

73. (Amended) A method for identifying an agent which is an inhibitor of a [fatty acid transport protein] Fatty Acid Transport Protein (FATP), comprising the steps of:
- (a) introducing into cells one or more vectors comprising a gene encoding a cell surface protein and a nucleic acid encoding the [fatty acid transport protein] FATP;
 - (b) contacting the host cells with anti-cell surface protein antibody and labeled fatty acid substrate of the [fatty acid transport protein] FATP;
 - (c) contacting a first aliquot of the host cells with an agent being tested as an inhibitor of the [fatty acid transport protein] FATP, while leaving a second aliquot of the host cells uncontacted with the agent;
 - (d) identifying, in the first and second aliquots, the host cells expressing the cell surface protein by detecting the anti-cell surface protein antibody bound to the host cells; and
 - (e) measuring, in the first and second aliquots, uptake of the fatty acid substrate of the host cells identified as expressing the cell surface protein;
- wherein less uptake of the fatty acid substrate in the first aliquot compared to the second aliquot is indicative that the agent is an inhibitor of the [fatty acid transport protein] FATP.